Finerenone (formerly known as BAY94-8862; BAY-948862; Kerendia) is a potent, selective, and orally bioavailable non-steroidal anti-mineralocorticoid or mineralocorticoid receptor (MR) antagonist (IC50 = 18 nM) that was approved in July 2021 by the US FDA to reduce the risk of kidney and heart complications in chronic kidney disease associated with type 2 diabetes. It was in phase III clinical trials for the treatment of chronic heart failure since October 2015. Finerenone has less relative affinity to other steroid hormone receptors than currently available antimineralocorticoids such as eplerenone and spironolactone, which should result in fewer adverse effects like gynaecomastia, impotence, and low sex drive.

纯度：≥98%

CAS：1050477-31-0